MAPK ERK Signaling Research Compounds: TargetMol Guide 2026

Researchers investigating the MAPK/ERK signaling cascade face a recurring challenge: finding tool compounds with verified purity, stable batch-to-batch performance, and sufficient target coverage to dissect a pathway that branches into ERK, p38 MAPK, JNK, and the upstream Raf/MEK axis. TargetMol Chemicals Inc., operating under the brand TargetMol/Targetmol, addresses this need through a dedicated MAPK signaling pathway catalog built on the same quality framework the company applies across its broader portfolio of 100,000+ inhibitors & agonists.

Why Compound Quality Matters for MAPK/ERK Studies

MAPK/ERK pathway research depends on generating reproducible dose-response data across multiple kinase nodes. According to TargetMol’s product positioning, small molecule inhibitors and agonists function as tool compounds that bind to targets such as proteins, genes, or RNA and reduce their biological activity. For pathway studies specifically, several recurring pain points shape compound selection:

• Inconsistent quality or unclear chemical composition between batches, which undermines comparability across experiments.
• Difficulty controlling dose and generating informative dose-response curves, a requirement when mapping kinase cascades.
• Dependence on transfection agents and poor cell permeability, which complicates cell-based MAPK assays.
• The need for compounds acting on specific targets within hot signaling pathways such as MAPK, rather than broad, non-specific modulators.

TargetMol’s stated differentiated value directly responds to these concerns: products are verified by HPLC, NMR, and LC/MS testing to confirm high purity and clear chemical composition, supporting reproducible experiments. The company also emphasizes that its compounds are more stable with low batch-to-batch variation, are cell-permeable without requiring transfection agents, and allow dose to be easily manipulated for precise dose-response work.

TargetMol’s MAPK Signaling Pathway Catalog

Within its signaling pathway product catalog, TargetMol lists a dedicated MAPK category spanning multiple kinase nodes relevant to ERK signaling research.

ERK and MEK-Targeting Compounds

The catalog includes ERK-focused entries such as NVP 231 (ID T1933, CAS 362003-83-6, Target: Apoptosis; ERK), BIX02189 (ID T21295, CAS 1265916-41-3, Target: ERK; MEK), Pluripotin (ID T6948, CAS 839707-37-8, Target: ERK; Raf; S6 Kinase, Condition: Phase 1/2, Indication: Gastric Cancer), DEL-22379 (ID T6818, CAS 181223-80-3, Target: Apoptosis; ERK), Ro-3306 (ID T2356, CAS 872573-93-8, Target: Apoptosis; CDK; ERK; PKA; PKC; SGK), and FR 180204 (ID T1956, CAS 865362-74-9, Target: Apoptosis; ERK). ISRIB (ID T2027, CAS 548470-11-7) targets PERK, extending coverage into the integrated stress response branch connected to MAPK signaling.

On the MEK side, the catalog provides GW 284543 hydrochloride (ID T7742, CAS 179246-08-3, Target: MEK), Ro 5126766 (ID T6971, CAS 946128-88-7, Target: MEK; Raf, Condition: Phase 1, Indication: Multiple Myeloma; Non-Small Cell Lung Cancer; Solid Tumours), GDC-0623 (ID T6843, CAS 1168091-68-6, Target: Apoptosis; MEK, Condition: Phase 1, Indication: Solid Tumours), Mirdametinib (ID T6189, CAS 391210-10-9, Target: Apoptosis; Autophagy; MEK, Condition: Phase 2; Preclinical, Indication: Chronic Obstructive Pulmonary Disease; Neurofibromatoses), Binimetinib (ID T2508, CAS 606143-89-9, Target: Autophagy; MEK, Condition: Marketed; Phase 3, Indication: Colorectal Cancer; Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer; Malignant Melanoma), CI-1040 (ID T2443, CAS 212631-79-3, Target: Apoptosis; MEK, Condition: Phase 2, Indication: Cancer), and PD 198306 (ID T21980, CAS 212631-61-3, Target: MEK).

p38 MAPK and JNK Compounds

Parallel MAPK branches are also represented. p38 MAPK entries include R1487 (ID T7667, CAS 449811-92-1), SD-169 (ID T7661, CAS 1670-87-7), Acumapimod (ID T7367, CAS 836683-15-9, Target: Autophagy; p38 MAPK), SD 0006 (ID T7276, CAS 271576-80-8, Target: Autophagy; p38 MAPK), anemarsaponin B (ID T7030, CAS 139051-27-7, Target: COX; MEK; NF-κB; NO Synthase; p38 MAPK), Losmapimod (ID T2277, CAS 585543-15-3, Target: Autophagy; p38 MAPK, Condition: Phase 3, Indication: Acute Coronary Syndromes), SC-514 (ID T2118, CAS 354812-17-2, Target: Aurora Kinase; CDK; IκB/IKK; p38 MAPK; Serine Protease), PH-797804 (ID T1974, CAS 586379-66-0, Target: Autophagy; p38 MAPK, Condition: Phase 2, Indication: Chronic Obstructive Pulmonary Disease; Musculoskeletal Pain; Neuropathic Pain; Rheumatoid Arthritis), and Adezmapimod (ID T1764, CAS 152121-47-6, Target: Autophagy; Mitophagy; p38 MAPK, Condition: Preclinical Discontinued, Indication: Cancer; Postmenopausal Osteoporosis; Rheumatoid Arthritis; Septic Shock).

JNK-related tools include Tanzisertib (ID T14895, CAS 899805-25-5, Condition: Phase 2, Indication: Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis; Fibrosis; Interstitial Lung Disease; Lung Diseases, Interstitial), Urolithin B (ID T13265, CAS 1139-83-9, Target: Akt; AMPK; Endogenous Metabolite; ERK; JNK; NF-κB), IQ-3 (ID T8477, CAS 312538-03-7), JNK Inhibitor VIII (ID T7677, CAS 894804-07-0), JNK-IN-8 (ID T2668, CAS 1410880-22-6, Target: c-Kit; JNK), AS601245 (ID T2343, CAS 345987-15-7, Condition: Phase 1 discontinued, Indication: Inflammation; Ischaemia), and TCS JNK 5a (ID T2234, CAS 312917-14-9, Target: Apoptosis; JNK).

Upstream Raf Pathway Compounds

Because ERK activation depends on upstream Raf signaling, the catalog also includes Raf-targeting compounds such as LXH254 (ID T11898, CAS 1800398-38-2, Condition: Phase 2, Indication: Melanoma), Sorafenib (ID T0093L, CAS 284461-73-0) and Sorafenib tosylate (ID T0093, CAS 475207-59-1), both marketed and targeting Apoptosis; Autophagy; c-Kit; Ferroptosis; FLT; PDGFR; Raf; VEGFR, Kobe2602 (ID T1892, CAS 454453-49-7, Target: Raf; Ras), TAK-632 (ID T1886, CAS 1228591-30-7, Target: Aurora Kinase; FGFR; PDGFR; Raf), Kobe0065 (ID T1876, CAS 436133-68-5, Target: Apoptosis; Raf; Ras), and ZM 336372 (ID T1851, CAS 208260-29-1, Target: Apoptosis; Raf).

This breadth allows investigators to select compounds targeting individual nodes—ERK, MEK, Raf, p38 MAPK, or JNK—while cross-referencing listed conditions (preclinical through marketed) and indications relevant to their disease models.

Verification, Supply, and Technical Support

Every compound in TargetMol’s catalog is positioned within a quality verification platform using HPLC, NMR, and LC/MS tests. This supports the company’s stated goal of delivering products with clear chemical composition and low variability between batches—factors that matter directly when comparing MEK or ERK inhibition across replicate experiments. TargetMol also states that in-stock catalog products ship within 1-2 days, supported by a global supply chain and professional technical support across the US, Europe, and Asia-Pacific regions.

Company Background

TargetMol Chemicals Inc. is headquartered in the Greater Boston area, Massachusetts, USA, with offices in Wellesley Hills (MA, USA), Linz (Austria), and Shanghai (China), and reports serving clients in 60+ countries and 8,000+ organizations. The company’s products have been cited in scientific literature including Nature, Cancer Cell, Cell, Immunity, Cell Research, Cancer Discovery, Gastroenterology, and Journal of Medical Virology, and TargetMol reports 15,000+ citations overall. The company received an award for a fast increase in the number of citations in 2023, was named Winner of the TargetMol Biochemical Supplier to Watch in 2023, and was recognized as a 2025 Bioz Rising Star Award Winner in the Inhibitor products catalog. Beyond catalog supply, TargetMol maintains in-house CADD (computer-aided drug design) and chemical synthesis capability, enabling customization for compounds not available directly from stock.

For MAPK/ERK pathway research specifically, this combination of catalog breadth across ERK, MEK, Raf, p38 MAPK, and JNK nodes, analytical verification methods, and global delivery infrastructure gives researchers a documented basis for selecting tool compounds suited to reproducible, dose-controlled signaling studies.

http://www.targetmol.com
TargetMol Chemicals Inc.